ABSTRACT Background Serum neurofilament‐light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are associated with multiple sclerosis (MS) activity. This study aimed to identify patient‐ and disease‐level determinants of sNfL and sGFAP and to evaluate their ability to support differential diagnosis in neuromyel...
M. Rival, F. Rollot, Sabine Laurent-Chabalier et al.· European Journal of Neurolog...· 0 citations
Key Points Question What is the long-term safety and efficacy profile of ocrelizumab in patients with relapsing multiple sclerosis (RMS)? Findings In the OPERA I/II randomized clinical trials including 1656 patients with RMS, treatment with ocrelizumab for up to 10 years led to near-complete and sustained suppression o...
Stephen L. Hauser, Amit Bar-Or, G. Giovannoni et al.· JAMA Neurology· 0 citations
BACKGROUND
Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple sclerosis (RRMS), but direct comparative evidence remains limited. We aimed to compare their effectiveness in routine clinical practice.
METHODS
We conducted an observational cohort study emulating...
Chao Zhu, S. Vukusic, T. Kalincik et al.· Journal of Neurology Neurosu...· 0 citations
BACKGROUND
Patient-reported outcomes (PROs) are collected in some multiple sclerosis (MS) care settings, yet their uses in MS clinical care are unclear.
OBJECTIVES
To determine how PROs are used in MS clinical care and gain insights into instruments, purposes, facilitators/barriers, and impact.
METHODS
Scoping revi...
M. Kuharic, C. Nowinski, Chelsea R. Perschon et al.· Multiple Sclerosis· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
